Personalizing treatment for chronic lymphocytic leukemia

Expert Review of Hematology

Volumn 4, Issue 1, 2011, Pages 27-35

  Abrisqueta, Pau ^a   Crespo, Marta ^a   Bosch, Francesc ^a  

^a Hospital Vall DHebron   (Spain)

Author keywords

chronic lymphocytic leukemia; comorbidity adjusted treatment; new therapeutic targets; resistance to treatment

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DASATINIB; FLAVOPIRIDOL; FLUDARABINE; FOSTAMATINAB; FOSTAMATINIB; GOSSYPOL; IMATINIB; ISOSORBIDE; LENALIDOMIDE; LUMILIZIMAB; METHYLPREDNISOLONE; MITOXANTRONE; OBATOCLAX; OBINUTUZUMAB; OBLIMERSEN; OFATUMOMAB; PENTOSTATIN; PIK 90; RITUXIMAB; ROSCOVITINE; STEROID; T 140; TC 14012; TN 14003; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME 11Q; CHROMOSOME 12; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; COMORBIDITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; GENE DELETION; HUMAN; IMMUNOMODULATION; MICROENVIRONMENT; MONOTHERAPY; NEUTROPENIA; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TRISOMY; TUMOR FLARE; TUMOR LYSIS SYNDROME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; INDIVIDUALIZED MEDICINE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-ABL; RECEPTORS, CXCR4; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; VIDARABINE;

EID: 79951802656     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.10.84     Document Type: Article

References (85)

1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N. Engl. J. Med. 333(16), 1052-1057 (1995).
2. Abrisqueta P, Pereira A, Rozman C, et al. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. Blood 114(10), 2044-2050 (2009).
3. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343(26), 1910-1916 (2000). (Pubitemid 32064784)
4. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85(6), 1580-1589 (1995).
5. Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J. Clin. Oncol. 25(7), 799-804 (2007). (Pubitemid 350010635)
6. Collins RJ, Verschuer LA, Harmon BV, Prentice RL, Pope JH, Kerr JF. Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br. J. Haematol. 71(3), 343-350 (1989). (Pubitemid 19086646)
7. Granziero L, Ghia P, Circosta P, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 97(9), 2777-2783 (2001).
8. Gine E, Martinez A, Villamor N, et al. Expanded and highly active proliferation tumors identify a histological subtype of chronic lymphocytic leukemia (accelerated chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 95(9), 1526-1533 (2010).
9. Pedersen IM, Kitada S, Leoni LM, et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 100(5), 1795-1801 (2002). (Pubitemid 34925159)
10. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J. Clin. Invest. 102(8), 1515-1525 (1998). (Pubitemid 28492218)
11. Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 111(2), 846-855 (2008).
12. Cuni S, Perez-Aciego P, Perez-Chacon G, et al. A sustained activation of PI3K/NF-kB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 18(8), 1391-1400 (2004). (Pubitemid 39136749)
13. Endo T, Nishio M, Enzler T, et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kB pathway. Blood 109(2), 703-710 (2007). (Pubitemid 46105972)
14. Hewamana S, Alghazal S, Lin TT, et al. The NF-kB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 111(9), 4681-4689 (2008).
15. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 343(24), 1750-1757 (2000).
16. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet 370(9583), 230-239 (2007). (Pubitemid 47069536)
17. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107(3), 885-891 (2006). (Pubitemid 43156283)
18. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J. Clin. Oncol. 25(7), 793-798 (2007). (Pubitemid 350002879)
19. Bosch F, Ferrer A, Villamor N, et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin. Cancer Res. 14(1), 155-161 (2008). (Pubitemid 351377991)
20. Keating MJ, OBrien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 23(18), 4079-4088 (2005). (Pubitemid 46211313)
21. Tam CS, OBrien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112(4), 975-980 (2008).
22. Bosch F, Abrisqueta P, Villamor N, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J. Clin. Oncol. 27(27), 4578-4584 (2009).
23. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, Phase 3 trial. Lancet 376(9747), 1164-1174 (2010).
24. Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98(1), 29-35 (2001).
25. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17(12), 2257-2317 (2003). (Pubitemid 38072572)
26. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J. Clin. Oncol. 23(13), 2971-2979 (2005). (Pubitemid 46224116)
27. Keating MJ, OBrien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk. Lymphoma 43(9), 1755-1762 (2002). (Pubitemid 34874007)
28. Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J. Clin. Oncol. 25(7), 799-804 (2007). (Pubitemid 350010635)
29. Shanafelt TD, Witzig TE, Fink SR, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J. Clin. Oncol. 24(28), 4634-4641 (2006). (Pubitemid 46630962)
30. Zenz T, Krober A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 112(8), 3322-3329 (2008).
31. Zenz T, Habe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114(13), 2589-2597 (2009).
32. Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin. Cancer Res. 15(3), 995-1004 (2009).
33. Dicker F, Herholz H, Schnittger S, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 23(1), 117-124 (2009).
34. Saddler C, Ouillette P, Kujawski L, et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 111(3), 1584-1593 (2008). (Pubitemid 351213449)
35. Barekati Z, Radpour R, Kohler C, et al. Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations. Hum. Mol. Genet. 19(15), 2936-2946 (2010).
36. Austen B, Skowronska A, Baker C, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J. Clin. Oncol. 25(34), 5448-5457 (2007). (Pubitemid 350232222)
37. Zenz T, Mohr J, Eldering E, et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 113(16), 3801-3808 (2009).
38. Deriano L, Guipaud O, Merle-Beral H, et al. Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway. Blood 105(12), 4776-4783 (2005). (Pubitemid 40807303)
39. Dreger P, Corradini P, Kimby E, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 21(1), 12-17 (2007). (Pubitemid 44921829)
40. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 25(35), 5616-5623 (2007).
41. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103(9), 3278-3281 (2004). (Pubitemid 38525651)
42. Osuji NC, Del Giudice I, Matutes E, Wotherspoon AC, Dearden C, Catovsky D. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 90(10), 1435-1436 (2005). (Pubitemid 41503660)
43. Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N. Engl. J. Med. 347(6), 452-453 (2002). (Pubitemid 34851846)
44. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol. 27(24), 3994-4001 (2009).
45. Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 92(10), 3804-3816 (1998). (Pubitemid 28525207)
46. Pepper C, Thomas A, Hoy T, et al. Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridol. Cell Cycle 2(1), 53-58 (2003).
47. Phelps MA, Lin TS, Johnson AJ, et al. Clinical response and pharmacokinetics from a Phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 113(12), 2637-2645 (2009).
48. Lin TS, Ruppert AS, Johnson AJ, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J. Clin. Oncol. 27(35), 6012-6018 (2009).
49. Alvi AJ, Austen B, Weston VJ, et al. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood 105(11), 4484-4491 (2005). (Pubitemid 40720798)
50. Thornton PD, Matutes E, Bosanquet AG, et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann. Hematol. 82(12), 759-765 (2003). (Pubitemid 38008843)
51. Pettitt AR, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 20(8), 1441-1445 (2006). (Pubitemid 44084061)
52. Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 22(11), 2048-2053 (2008).
53. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br. J. Haematol. 92(1), 97-103 (1996). (Pubitemid 26018774)
54. +, CD40L+ T cells by producing CCL22. Eur. J. Immunol. 32(5), 1403-1413 (2002). (Pubitemid 34546268)
55. Burger JA, Tsukada N, Burger M, Zvaifler NJ, DellAquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 96(8), 2655-2663 (2000).
56. Chen H, Treweeke AT, West DC, et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood 96(9), 3181-3187 (2000).
57. Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 114(16), 3382-3391 (2009).
58. Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk. Lymphoma 49(1), 49-56 (2008). (Pubitemid 351146882)
59. Extermann M. Measuring comorbidity in older cancer patients. Eur. J. Cancer 36(4), 453-471 (2000). (Pubitemid 30136223)
60. Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 27(4), 498-503 (2009).
61. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115(13), 2578-2585 (2010).
62. Burger M, Hartmann T, Krome M, et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 106(5), 1824-1830 (2005). (Pubitemid 41208600)
63. Niedermeier M, Hennessy BT, Knight ZA, et al. Isoform-selective phosphoinositide 3-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 113(22), 5549-5557 (2009).
64. Lapalombella R, Andritsos L, Liu Q, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood 115(13), 2619-2629 (2010).
65. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a Phase II study. J. Clin. Oncol. 24(34), 5343-5349 (2006). (Pubitemid 46623164)
66. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111(11), 5291-5297 (2008).
67. Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J. Clin. Oncol. 26(15), 2519-2525 (2008).
68. Hallaert DY, Jaspers A, van Noesel CJ, van Oers MH, Kater AP, Eldering E. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood 112(13), 5141-5149 (2008).
69. OBrien S, Moore JO, Boyd TE, et al. Randomized Phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol. 25(9), 1114-1120 (2007). (Pubitemid 46596764)
70. Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 112(5), 1971-1980 (2008).
71. Balakrishnan K, Burger JA, Wierda WG, Gandhi V. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 113(1), 149-153 (2009).
72. OBrien SM, Claxton DF, Crump M, et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113(2), 299-305 (2009).
73. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-kB activity and apoptosis in chronic lymphocytic leukemia B cells. J. Immunol. 164(4), 2200-2206 (2000). (Pubitemid 30108780)
74. Hewamana S, Lin TT, Jenkins C, et al. The novel nuclear factor-kB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clin. Cancer Res. 14(24), 8102-8111 (2008).
75. Faderl S, Rai K, Gribben J, et al. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer 107(5), 916-924 (2006). (Pubitemid 44291139)
76. Zent CS, LaPlant BR, Johnston PB, et al. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 116(9), 2201-2207 (2010).
77. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 107(10), 4109-4114 (2006). (Pubitemid 43726820)
78. Kojima K, Konopleva M, McQueen T, OBrien S, Plunkett W, Andreeff M. MDM2 inhibitor nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome ATM-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 108(3), 993-1000 (2006). (Pubitemid 44154636)
79. Pathan NI, Chu P, Hariharan K, Cheney C, Molina A, Byrd J. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood 111(3), 1594-1602 (2008). (Pubitemid 351213450)
80. Byrd JC, Kipps TJ, Flinn IW, et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 115(3), 489-495 (2010).
81. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a Phase 1-2 study. Blood 111(3), 1094-1100 (2008). (Pubitemid 351213387)
82. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 28(10), 1749-1755 (2010).
83. Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115(22), 4393-4402 (2010).
84. Clinicaltrials.gov: CLL11: a study of RO5072759 with chlorambucil in patients with previously untreated chronic lymphocytic leukemia http://clinicaltrials.gov/ct2/show/ NCT01010061
85. Clinicaltrials.gov: Evaluation of safety and efficacy of fludarabine, cyclophosphamide, and rituximab (FCR) +/-lumiliximab in subjects with previously untreated chronic lymphocytic leukemia (CLL) http://clinicaltrials.gov/ct2/ show/ NCT00801060